Spots Global Cancer Trial Database for japanese
Every month we try and update this database with for japanese cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients | NCT00960349 | Gastric Cancer | Cediranib Cisplatin S-1 Cisplatin Capecitabine | 20 Years - | AstraZeneca | |
| Japanese BAY1000394 Monotherapy Phase I Study | NCT02047890 | Neoplasms | BAY1000394 (2.5... BAY1000394 (5mg... | 20 Years - | Bayer | |
| Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel | NCT01000896 | Cancer Non Small Cell ... Epithelial Ovar... | AZD0530 Carboplatin paclitaxel | 20 Years - | AstraZeneca | |
| Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects | NCT01340040 | Cancer Advanced Solid ... | MEDI-573 | 18 Years - | AstraZeneca | |
| A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors | NCT01832506 | Solid Tumors | MSC2156119J | 20 Years - | Merck KGaA, Darmstadt, Germany | |
| Japanese BAY1000394 Monotherapy Phase I Study | NCT02047890 | Neoplasms | BAY1000394 (2.5... BAY1000394 (5mg... | 20 Years - | Bayer | |
| A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies | NCT01957579 | Blood Cancer Advanced B Cell... | MEDI-551 | 20 Years - 130 Years | AstraZeneca | |
| Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer | NCT01938456 | Lung Cancer, No... | Trametinib Docetaxel Filgrastim | 20 Years - | GlaxoSmithKline | |
| Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC | NCT02824094 | Neoplasms Carcinoma, Non-... | crizotinib | 20 Years - | Pfizer | |
| Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients | NCT00960349 | Gastric Cancer | Cediranib Cisplatin S-1 Cisplatin Capecitabine | 20 Years - | AstraZeneca | |
| Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055 | NCT00973076 | Cancer Solid Tumors Advanced Solid ... | AZD8055 | 20 Years - | AstraZeneca | |
| Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma | NCT02598570 | Lymphoma | duvelisib | 20 Years - 99 Years | AbbVie | |
| A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors | NCT01832506 | Solid Tumors | MSC2156119J | 20 Years - | Merck KGaA, Darmstadt, Germany | |
| Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC | NCT02824094 | Neoplasms Carcinoma, Non-... | crizotinib | 20 Years - | Pfizer | |
| Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects | NCT01340040 | Cancer Advanced Solid ... | MEDI-573 | 18 Years - | AstraZeneca | |
| Japanese BAY80-6946 Monotherapy Phase I Study | NCT01404390 | Neoplasms | BAY80-6946 BAY80-6946 | 20 Years - 80 Years | Bayer | |
| Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel | NCT01000896 | Cancer Non Small Cell ... Epithelial Ovar... | AZD0530 Carboplatin paclitaxel | 20 Years - | AstraZeneca | |
| A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan | NCT04043975 | Advanced or Met... | 20 Years - | Bristol-Myers Squibb | ||
| Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient | NCT01213160 | Cancer Advanced Solid ... | AZD4547 | 25 Years - 150 Years | AstraZeneca | |
| A Study of EMD525797 in Solid Tumor Patients in Japan | NCT01327313 | Solid Tumor | EMD525797 EMD525797 EMD525797 EMD525797 | 20 Years - | Merck KGaA, Darmstadt, Germany | |
| An Open Label Prostate Cancer Study in Japanese Patients | NCT01351688 | Prostate Cancer | AZD3514 | 20 Years - | AstraZeneca | |
| Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma | NCT02598570 | Lymphoma | duvelisib | 20 Years - 99 Years | AbbVie | |
| Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects | NCT01340040 | Cancer Advanced Solid ... | MEDI-573 | 18 Years - | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
